Home Biomarkers Circulating Tumor Cell

Circulating Tumor Cell

Latest
Biocept will partner with Providence St. Joseph Health
Circulating Tumor Cell

Providence St. Joseph Health, 2 Affiliates to Study Using CSF with...

Circulating Tumor Cell

Circulating Tumor Cells Isolated Efficiently with New Microfluidic Device

CellMax Life's CMxTM circulating tumor cell (CTC) platform and liquid biopsy panel will be used by Medigen Biotech in upcoming clinical trials of its cell therapy candidates for cancers
Circulating Tumor Cell

Medigen to Use CellMax Life CTC Blood Test in Trials of...

Sysmex and MolecularMD will partner to develop and commercialize companion diagnostics for precision medicines through a master collaboration agreement whose value was not disclosed.[© Alex Tihonov/Fotolia]
Circulating Tumor Cell

Sysmex, MolecularMD Partner on Precision Medicine Companion Diagnostics

Epic Sciences is partnering with four Canadian breast cancer centers to carry out a clinical validation trial of the company’s blood test
Circulating Tumor Cell

Epic Sciences, Four Canadian Breast Cancer Centers Launch Trial of Blood...

Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment. [Source: © Alex Tihonov/Fotolia]
Circulating Tumor Cell

Study Shows Epic Sciences Liquid Biopsy Aids Prostate Cancer Patient Selection

Bristol-Myers Squibb (BMS) plans to use Natera's Signatera custom circulating tumor DNA (ctDNA) assay in a Phase II study designed to assess the pharma giant’s cancer immunotherapy Opdivo (nivolumab) as an adjuvant treatment for non-small cell lung cancer (NSCLC). [Source: Eraxion/Getty]
Circulating Tumor Cell

BMS to Use Natera’s Signatera ctDNA Assay in Adjuvant Opdivo NSCLC...

Source: WLADIMIR BULGAR/Getty Images
Circulating Tumor Cell

Malaria Protein Employed for Collecting Circulating Tumor Cells

Biocept will evaluate the clinical utility and cost effectiveness of using Biocept's Target Selector testing in patients diagnosed with non-small cell lung cancer (NSCLC)
Circulating Tumor Cell

Biocept to Study Clinical Utility, Cost Effectiveness of Assays in NSCLC...

Biocept will partner with Moores Cancer Center at University of California (UC) San Diego Health to conduct two clinical studies in patients with a variety of solid tumors
Circulating Tumor Cell

Biocept, UCSD Plan Clinical Studies of Liquid Biopsy Assays in Solid...

Load more

New Products

View More
Load more

News Briefs

View More
Load more
Copyright © 2019 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up